PepGen Inc. Reports Q1 2025 Financial Results

PepGen Inc. ( (PEPG) ) has released its Q1 earnings. Here is a breakdown of the information PepGen Inc. presented to its investors.

PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for treating severe neuromuscular and neurologic diseases, based in Boston, Massachusetts. In its latest earnings report, PepGen Inc. highlighted significant financial activities and operational updates for the quarter ending March 31, 2025. The company reported a net loss of $30.2 million, an increase from the $18.0 million loss in the same period last year, primarily due to increased research and development expenses. Despite the losses, PepGen maintains a strong cash position with $97.8 million in cash, cash equivalents, and marketable securities, which is expected to support operations for at least the next 12 months. The company continues to advance its clinical trials, with a focus on its lead product candidates, PGN-EDO51 and PGN-EDODM1, although it has paused one of its Phase 2 trials voluntarily. Looking ahead, PepGen plans to continue its development efforts and explore additional funding opportunities to support its strategic goals.